

Gender: Female | Birth year: 1946 | WHO: 0

Tumor: Colorectum (cecum) carcinoma | Lesions: Lung, Peritoneal | Stage: IV

Clinical summary

Relevant systemic treatment history	None	
Relevant other oncological history	11/2021	Hemicolectomy right (Cecum)
Previous primary tumor	Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)	
Relevant non-oncological history	1/2019	Cerebrovascular accident

Standard-of-care options considered potentially eligible

Treatment	Literature efficacy evidence	Real-world efficacy evidence	Warnings
FOLFIRI	PHASE-3-CRC		
	PFS: 10.0 months (95% CI: 10.0-12.0)	PFS: 13.3 months, IQR: 12.6	
	OS: 25.0 months (95% CI: 25.0-30.0)	OS: 22.2 months, IQR: 24.8	

Trials in NL that are open and potentially eligible (1 cohort from 1 trial)

Trial	Cohort	Molecular	Sites	Warnings
KRAS-G12D-TRIAL	KRAS G12D	KRAS G12D	UMC Utrecht	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

Molecular Details

NGS & MSI Panel (15-Jan-2023)

Biopsy location	Lung
Tumor mutational burden	TMB 8 mut/Mb
Microsatellite (in)stability	Stable
Driver mutations	KRAS G12D

IHC results

Ki67	Positive, score 90%
PD-L1	Score < 50%

Efficacy evidence

Standard of care options considered potentially eligible

The following standard of care treatment(s) could be an option for this patient. For further details per study see 'SOC literature details' section in extended report.

Treatment	Literature efficacy evidence												
FOLFIRI	<div>PHASE-3-CRC Patient characteristics:<table><tr><td>WHO/ECOG</td><td>0: 100, 1: 80, 2: 20, 3: 0, 4: 0</td></tr><tr><td>Primary tumor location</td><td>Left: 145, Both or unknown: 10, Right: 45</td></tr><tr><td>Mutations</td><td>KRAS exon 2 wild-type 200/200</td></tr><tr><td>Metastatic sites</td><td>Liver only: 58 (32.0%), Lung only: 10 (6.0%)</td></tr><tr><td>Previous systemic therapy</td><td>35/200</td></tr><tr><td>Prior therapies</td><td>Adjuvant chemotherapy</td></tr></table> Median PFS: 10.0 months (95% CI: 10.0-12.0) Median OS: 25.0 months (95% CI: 25.0-30.0)</div>	WHO/ECOG	0: 100, 1: 80, 2: 20, 3: 0, 4: 0	Primary tumor location	Left: 145, Both or unknown: 10, Right: 45	Mutations	KRAS exon 2 wild-type 200/200	Metastatic sites	Liver only: 58 (32.0%), Lung only: 10 (6.0%)	Previous systemic therapy	35/200	Prior therapies	Adjuvant chemotherapy
WHO/ECOG	0: 100, 1: 80, 2: 20, 3: 0, 4: 0												
Primary tumor location	Left: 145, Both or unknown: 10, Right: 45												
Mutations	KRAS exon 2 wild-type 200/200												
Metastatic sites	Liver only: 58 (32.0%), Lung only: 10 (6.0%)												
Previous systemic therapy	35/200												
Prior therapies	Adjuvant chemotherapy												

Treatment decisions (percentage of population assigned to systemic treatment) in NCR real-world data set

	All (n=9207)	Age 73-83y (n=2727)	WHO 1 (n=2828)	RAS positive (n=2760)	Liver only lesions (n=2715)
FOLFIRI	38.5%	23.8%	37.9%	44.6%	39.5%

Median overall survival (OS) in months in NCR real-world data set

	All (n=9207)	Age 73-83y (n=2727)	WHO 1 (n=2828)	RAS positive (n=2760)	Liver only lesions (n=2715)
FOLFIRI	16.1, IQR: 18.2 (n=3543)	15.4, IQR: 18.2 (n=649)	14.8, IQR: 16.3 (n=1071)	15.8, IQR: 14.2 (n=1230)	16.5, IQR: 17.4 (n=1073)

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report. Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).

Median progression-free survival (PFS) in months in NCR real-world data set

	All (n=5018)	Age 73-83y (n=1330)	WHO 1 (n=1623)	RAS positive (n=1822)	Liver only lesions (n=1534)
FOLFIRI	8.2, IQR: 5.5 (n=2106)	8, IQR: 6.1 (n=340)	7.9, IQR: 5 (n=661)	8, IQR: 4.7 (n=836)	8.3, IQR: 5.3 (n=652)

Explanation:

These tables only show treatments that are considered standard of care (SOC) in colorectal cancer in the Netherlands.


The 'All' column shows results in NCR patients who were previously untreated, diagnosed with colorectal cancer with distant metastases and treated systemically without surgery, for whom the treatment could be categorized in SOC treatments.

The 'Age', 'WHO', 'RAS' and 'Lesions' columns show results based on patients from the 'All' population, filtered for equal WHO, similar age, equal RAS status or equal lesion localization, respectively.


'PFS' is calculated as the duration from the date on which the first compound of the treatment was administered, until first progression.

'OS' is calculated as the duration from the date on which the first compound of the treatment was administered, until death from any cause.


When patient number is too low (n <= 20) to predict PFS or OS, "NA" is shown.




y



y





Resistance evidence

Treatment	Mutation	Evidence source	Evidence level	Found in molecular analysis
FOLFIRI	GENE S11C	[1]	D	Yes

Clinical Details

Clinical summary

Relevant systemic treatment history	None	
Relevant other oncological history	11/2021	Hemicolectomy right (Cecum)
Previous primary tumor	Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)	
Relevant non-oncological history	1/2019	Cerebrovascular accident

Patient current details (05-Mar-2023)

Unresolved toxicities grade => 2	None
Known allergies	Morphine
Recent surgeries	12-Nov-2021 Hemicolectomy right

Tumor details (05-Mar-2023)

Measurable disease	Yes
Known lesions	Lung, Peritoneal
Unknown lesions	Lymph node
No lesions present	CNS, Brain, Liver, Bone

Active medication details

Medication	Administration route	Start date	Stop date	Dosage	Frequency
None					

Blood transfusions

Product	Date
ERTHROCYTES_FILTERED	10-Jan-2023

Trial Matching Details

Trials and cohorts that are potentially eligible, but are closed (2)

Trial	Cohort	Molecular	Sites	Warnings
METC 01 IEMOEN	Applies to all cohorts below	None		Has not exhausted SOC
	Dose escalation - monotherapy			
	Dose expansion - monotherapy			

Trials and cohorts that are considered ineligible (2)

Trial	Cohort	Molecular	Ineligibility reasons
METC 02 KAYRAS	Applies to all cohorts below	KRAS G12D	PD-L1 expression below minimum of 50.0
	Dose expansion - monotherapy - Colorectum		No lung non-small cell carcinoma
	Dose expansion - monotherapy - NSCLC		

Trials and cohorts that are not evaluable or ignored (0)

Trial	Cohort	Molecular	Sites	Configuration
None				